| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.4 |